Mycophenolatmofetil Alkem (Mycophenolate Mofetil)

Mycophenolate Mofetil is used in immunosuppressive therapy to control immune‑mediated processes.

• Kidney transplant rejection: helps maintain graft function by suppressing the immune response.
• Heart and liver transplant rejection: reduces the risk of acute rejection episodes.
• Lupus nephritis: contributes to disease control by decreasing renal inflammation.

• Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme for de novo guanosine nucleotide synthesis in lymphocytes. This blockade lowers intracellular guanosine pools, impairing DNA synthesis and proliferation of activated T and B cells, thereby dampening the adaptive immune response.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain.
• Infections: increased susceptibility to bacterial, viral or fungal infections.
• Hematologic changes: anemia, leukopenia, or thrombocytopenia.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Malignancy risk: increased incidence of lymphoproliferative disorders or skin cancers.
• Pregnancy complications: teratogenic effects leading to fetal loss or birth defects.

When prescribing Mycophenolate Mofetil, clinicians should consider several safety precautions.

• Monitor blood counts: regular CBC testing to detect cytopenias.
• Assess renal function: dose adjustments may be needed in impaired kidneys.
• Screen for infections: evaluate for latent viral infections before initiation.
• Avoid live vaccines: immunosuppression can reduce vaccine efficacy and increase risk.
• Pregnancy risk: contraindicated in pregnancy due to teratogenicity; use effective contraception.
• Store at ambient temperature: keep below 25 °C in the original pack, protect from moisture.

Mycophenolate Mofetil interacts with several drugs that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption of Mycophenolate.
• Azathioprine: additive bone marrow suppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly decrease drug levels.

Moderate Interactions (Monitor Closely)

• Tacrolimus or cyclosporine: may increase risk of nephrotoxicity.
• Vaccines: live attenuated vaccines may cause infection.
• Cholestyramine: can bind and lower drug concentration.